Skeletal muscle remodeling

Matthew J. Potthoff, Eric N. Olson, Rhonda Bassel-Duby

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: In skeletal muscle, environmental demands activate signal transduction pathways that ultimately promote adaptive changes in myofiber cytoarchitecture and protein composition. Recent advances in determining the factors involved in these signal transduction pathways provide insight into possible therapeutic methods to remodel skeletal muscle. RECENT FINDINGS: Advances in genetic engineering have allowed the introduction or depletion of factors within the myofiber, facilitating the evaluation of signaling factors during muscle remodeling. Using transgenic mouse models, activation of specific signaling pathways promoted type I oxidative myofibers, increased the fatigue resistance of muscle, increased skeletal muscle mass and ameliorated muscle injury in myopathic mouse models. Moreover, new technologies are being used to generate global gene and protein expression profiles to identify new factors involved in skeletal muscle remodeling. Finally, small RNAs, microRNAs, are emerging as powerful regulators of gene expression in most tissues, including skeletal muscle. Recent findings predict that targeted delivery of miRNAs will specifically manipulate genes and if used therapeutically will revolutionize clinical medicine. SUMMARY: Developing drugs to target signaling pathways associated with remodeling myofibers provides a possible therapeutic approach to combat skeletal muscle disease. In addition, genome-wide technologies can identify new biomarkers capable of diagnosing myopathies and determine a patient's response to therapy. Furthermore, therapeutic strategies are being designed to target microRNAs in anticipation of blocking gene repression correlated with muscle pathology.

Original languageEnglish (US)
Pages (from-to)542-549
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume19
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Skeletal Muscle
MicroRNAs
Muscles
Signal Transduction
Technology
Muscle Fatigue
Genetic Engineering
Clinical Medicine
Muscular Diseases
Therapeutics
Regulator Genes
Transcriptome
Transgenic Mice
Genes
Proteins
Biomarkers
Genome
RNA
Pathology
Gene Expression

Keywords

  • Atrophy
  • Hypertrophy
  • Myofiber
  • Myopathy
  • Signal transduction pathway

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Skeletal muscle remodeling. / Potthoff, Matthew J.; Olson, Eric N.; Bassel-Duby, Rhonda.

In: Current Opinion in Rheumatology, Vol. 19, No. 6, 11.2007, p. 542-549.

Research output: Contribution to journalArticle

Potthoff, Matthew J. ; Olson, Eric N. ; Bassel-Duby, Rhonda. / Skeletal muscle remodeling. In: Current Opinion in Rheumatology. 2007 ; Vol. 19, No. 6. pp. 542-549.
@article{be3e6baeb8fe4066bf164fca1bf423e0,
title = "Skeletal muscle remodeling",
abstract = "PURPOSE OF REVIEW: In skeletal muscle, environmental demands activate signal transduction pathways that ultimately promote adaptive changes in myofiber cytoarchitecture and protein composition. Recent advances in determining the factors involved in these signal transduction pathways provide insight into possible therapeutic methods to remodel skeletal muscle. RECENT FINDINGS: Advances in genetic engineering have allowed the introduction or depletion of factors within the myofiber, facilitating the evaluation of signaling factors during muscle remodeling. Using transgenic mouse models, activation of specific signaling pathways promoted type I oxidative myofibers, increased the fatigue resistance of muscle, increased skeletal muscle mass and ameliorated muscle injury in myopathic mouse models. Moreover, new technologies are being used to generate global gene and protein expression profiles to identify new factors involved in skeletal muscle remodeling. Finally, small RNAs, microRNAs, are emerging as powerful regulators of gene expression in most tissues, including skeletal muscle. Recent findings predict that targeted delivery of miRNAs will specifically manipulate genes and if used therapeutically will revolutionize clinical medicine. SUMMARY: Developing drugs to target signaling pathways associated with remodeling myofibers provides a possible therapeutic approach to combat skeletal muscle disease. In addition, genome-wide technologies can identify new biomarkers capable of diagnosing myopathies and determine a patient's response to therapy. Furthermore, therapeutic strategies are being designed to target microRNAs in anticipation of blocking gene repression correlated with muscle pathology.",
keywords = "Atrophy, Hypertrophy, Myofiber, Myopathy, Signal transduction pathway",
author = "Potthoff, {Matthew J.} and Olson, {Eric N.} and Rhonda Bassel-Duby",
year = "2007",
month = "11",
doi = "10.1097/BOR.0b013e3282efb761",
language = "English (US)",
volume = "19",
pages = "542--549",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Skeletal muscle remodeling

AU - Potthoff, Matthew J.

AU - Olson, Eric N.

AU - Bassel-Duby, Rhonda

PY - 2007/11

Y1 - 2007/11

N2 - PURPOSE OF REVIEW: In skeletal muscle, environmental demands activate signal transduction pathways that ultimately promote adaptive changes in myofiber cytoarchitecture and protein composition. Recent advances in determining the factors involved in these signal transduction pathways provide insight into possible therapeutic methods to remodel skeletal muscle. RECENT FINDINGS: Advances in genetic engineering have allowed the introduction or depletion of factors within the myofiber, facilitating the evaluation of signaling factors during muscle remodeling. Using transgenic mouse models, activation of specific signaling pathways promoted type I oxidative myofibers, increased the fatigue resistance of muscle, increased skeletal muscle mass and ameliorated muscle injury in myopathic mouse models. Moreover, new technologies are being used to generate global gene and protein expression profiles to identify new factors involved in skeletal muscle remodeling. Finally, small RNAs, microRNAs, are emerging as powerful regulators of gene expression in most tissues, including skeletal muscle. Recent findings predict that targeted delivery of miRNAs will specifically manipulate genes and if used therapeutically will revolutionize clinical medicine. SUMMARY: Developing drugs to target signaling pathways associated with remodeling myofibers provides a possible therapeutic approach to combat skeletal muscle disease. In addition, genome-wide technologies can identify new biomarkers capable of diagnosing myopathies and determine a patient's response to therapy. Furthermore, therapeutic strategies are being designed to target microRNAs in anticipation of blocking gene repression correlated with muscle pathology.

AB - PURPOSE OF REVIEW: In skeletal muscle, environmental demands activate signal transduction pathways that ultimately promote adaptive changes in myofiber cytoarchitecture and protein composition. Recent advances in determining the factors involved in these signal transduction pathways provide insight into possible therapeutic methods to remodel skeletal muscle. RECENT FINDINGS: Advances in genetic engineering have allowed the introduction or depletion of factors within the myofiber, facilitating the evaluation of signaling factors during muscle remodeling. Using transgenic mouse models, activation of specific signaling pathways promoted type I oxidative myofibers, increased the fatigue resistance of muscle, increased skeletal muscle mass and ameliorated muscle injury in myopathic mouse models. Moreover, new technologies are being used to generate global gene and protein expression profiles to identify new factors involved in skeletal muscle remodeling. Finally, small RNAs, microRNAs, are emerging as powerful regulators of gene expression in most tissues, including skeletal muscle. Recent findings predict that targeted delivery of miRNAs will specifically manipulate genes and if used therapeutically will revolutionize clinical medicine. SUMMARY: Developing drugs to target signaling pathways associated with remodeling myofibers provides a possible therapeutic approach to combat skeletal muscle disease. In addition, genome-wide technologies can identify new biomarkers capable of diagnosing myopathies and determine a patient's response to therapy. Furthermore, therapeutic strategies are being designed to target microRNAs in anticipation of blocking gene repression correlated with muscle pathology.

KW - Atrophy

KW - Hypertrophy

KW - Myofiber

KW - Myopathy

KW - Signal transduction pathway

UR - http://www.scopus.com/inward/record.url?scp=34948886117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948886117&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e3282efb761

DO - 10.1097/BOR.0b013e3282efb761

M3 - Article

C2 - 17917533

AN - SCOPUS:34948886117

VL - 19

SP - 542

EP - 549

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -